Last update 08 May 2025

Brillian Pharma, Inc.

Private Company|2018|United States|
brillianpharma.com

Overview

Tags

Neoplasms
Cardiovascular Diseases
Other Diseases
Chemical drugs
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
no Data
No Data
Disease DomainCount
Hemic and Lymphatic Diseases2
Neoplasms2
Nervous System Diseases1
Top 5 Drug TypeCount
Chemical drugs6
Small molecule drug1

Related

25
Drugs associated with Brillian Pharma, Inc.
BP-111(Brillian Pharma)
Target-
Mechanism-
Active Org.
Brillian Pharma, Inc.
Originator Org.
Brillian Pharma, Inc.
Active Indication
Hypertension
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
BP-114
Target-
Mechanism-
Active Org.
Brillian Pharma, Inc.
Originator Org.
Brillian Pharma, Inc.
Active Indication
Attention Deficit Disorder With Hyperactivity
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
BP-116
Target-
Mechanism-
Active Org.
Brillian Pharma, Inc.
Originator Org.
Brillian Pharma, Inc.
Active Indication
Philadelphia chromosome positive chronic myelogenous leukemia
Inactive Indication-
Drug Highest PhasePreclinical
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Brillian Pharma, Inc.
CTRI/2024/07/071015
/ CompletedNot Applicable
An Open Label Balanced Randomized Single Dose Three Treatment Three Sequence Three Period Three Way Crossover Oral Comparative Bioavailability Study of Guanfacine For Extended Release Suspension 4 mg Manufactured by Sciecure Pharma Inc (Subsidary Of Brillian Pharma Inc.) with Intuniv (Guanfacine Hydrochloride) 4 mg Extended Release Tablets Manufactured by Takeda Pharmaceuticals USA in Healthy Male And Female Adult Human Subjects Under Fasting Conditions - NIL
100 Clinical Results associated with Brillian Pharma, Inc.
Login to view more data
0 Patents (Medical) associated with Brillian Pharma, Inc.
Login to view more data
100 Deals associated with Brillian Pharma, Inc.
Login to view more data
100 Translational Medicine associated with Brillian Pharma, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
7
18
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
BP-112
Seizures
More
Preclinical
BP-115
Hypertension
More
Preclinical
BP-110
Attention Deficit Disorder With Hyperactivity
More
Preclinical
BP-111(Brillian Pharma)
Hypertension
More
Preclinical
BP-116
Philadelphia chromosome positive chronic myelogenous leukemia
More
Preclinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free